WallStSmart

Insmed Inc (INSM)vsSerina Therapeutics Inc (SER)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 522678% more annual revenue ($606.42M vs $116,000). SER leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

SER

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: -13.82

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

SER0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

SER4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

Market CapQuality
$27.40M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Debt/EquityHealth
1.823/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : SER

SER has a balanced fundamental profile.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : SER

The primary concerns for SER are Revenue Growth, Market Cap, Profit Margin. Debt-to-equity of 1.82 is elevated, increasing financial risk.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while SER is a value play — different risk/reward profiles.

SER is growing revenue faster at 1.5% — sustainability is the question.

SER generates stronger free cash flow (-4M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Serina Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Serina Therapeutics Inc is a forward-thinking biotechnology company focused on developing innovative therapies for unmet medical needs, particularly in oncology and neurology. Leveraging its proprietary polymer-based drug delivery platform, Serina enhances therapeutic efficacy to improve patient outcomes. With a robust pipeline of product candidates, the company is well-positioned for sustainable growth in the biopharmaceutical sector. Its dedication to advanced technology and strategic collaborations reflects its commitment to transforming healthcare solutions and creating value for investors.

Visit Website →

Want to dig deeper into these stocks?